China’s NHSA Aims to Boost Medical Insurance Reform with Sanming Model
The National Healthcare Security Administration (NHSA) has issued a notification aimed at promoting the medical...
Policy / Regulatory
NMPA Releases 80th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 80th batch of reference drugs for...
Guangzhou Boosts Innovative Drug Development with New HSA Initiatives
The Healthcare Security Administration (HSA) bureau in Guangzhou’s province has issued a notification outlining measures...
China’s NMPA and NHC Tighten Control on Psychotropic Substances with New Regulations
The National Medical Products Administration (NMPA) and the National Health Commission (NHC) of China have...
FDA Alert: Chinese Syringe Maker Jiangsu Shenli Initiates Voluntary Recall
This week, the US Food and Drug Administration (FDA) provided a status report on its...
China’s CDE Reports Record High in Clinical Trials for Innovative Drugs in 2023
The Center for Drug Evaluation (CDE) has released its annual report, highlighting the growth in...
NHSA Unveils 2024 Medical Procurement Overhaul, Aiming for Synergy Between National and Provincial Levels
The National Healthcare Security Administration (NHSA) has issued a notification detailing plans to enhance the...
China and South Korea Reinforce Ties with Renewed MOU on Pharmaceuticals and Cosmetics Regulation
The National Medical Products Administration (NMPA) of China and the Ministry of Food and Drug...
China’s Health Commission Boosts Efforts to Monitor and Respond to Drug Shortages
The National Health Commission (NHC) of China has recently announced the reinforcement of national and...
Landmark Biosecure Act Passes US House Committee with 40-1 Vote, Eyes 2024 Enactment
The US House Committee on Oversight and Accountability has completed the markup process for amendments...
US Readies Hefty Tariffs on Chinese Medical Equipment and Other Imports
The US Office of the Trade Representative (USTR) has announced a series of stringent new...
China Launches Nationwide Unannounced Inspections of Medical Insurance Funds
An inaugural meeting for the first batch of unannounced medical insurance fund inspections was conducted...
NMPA Seeks Public Comment on Draft Proposal for Drug Re-Registration Procedures
The National Medical Products Administration (NMPA) of China has released a draft proposal for the...
NMPA Updates In Vitro Diagnostic Reagents Classification List for Enhanced Regulatory Oversigh
The National Medical Products Administration (NMPA) has coordinated the revision and release of the In...
China’s NMPA Revamps Medical Device Classification Rules to Improve Regulatory Efficiency
The National Medical Products Administration (NMPA) has revised the “Notice on Standardizing the Classification of...
BIO Survey Highlights Extensive Dependence on Chinese CDMOs in Life Sciences
The Biotechnology Innovation Organization (BIO), a US industry trade group, has completed a survey among...
BioSecure Act Advances in US, Aiming to Curb Ties with Chinese Bioscience Firms
US legislators are working expeditiously to finalize the BioSecure Act, legislation that, if enacted, would...
China Unveils Sweeping 2024 Legislative Plan with Healthcare and Pharma at Forefront
The State Council of China has released its annual legislative work plan for 2024, outlining...
Hong Kong SAR and NMPA Renew Agreements to Boost Drug and Medical Device Regulation
Professor Chung-mau LO, BBS, JP, Secretary for Health of the Hong Kong Special Administrative Region...
Xi and Macron Discuss Enhanced Market Access for Foreign Investors, Focus on Life Sciences
This week, talks between China’s President Xi Jinping and France’s President Emmanuel Macron in France...